13 results on '"Mosseri, V."'
Search Results
2. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
- Author
-
Schleiermacher, G, Mosseri, V, London, WB, Maris, JM, Brodeur, GM, Attiyeh, E, Haber, M, Khan, J, Nakagawara, A, Speleman, F, Noguera, R, Tonini, GP, Fischer, M, Ambros, I, Monclair, T, Matthay, KK, Ambros, P, Cohn, SL, Pearson, ADJ, Schleiermacher, G, Mosseri, V, London, WB, Maris, JM, Brodeur, GM, Attiyeh, E, Haber, M, Khan, J, Nakagawara, A, Speleman, F, Noguera, R, Tonini, GP, Fischer, M, Ambros, I, Monclair, T, Matthay, KK, Ambros, P, Cohn, SL, and Pearson, ADJ
- Abstract
BACKGROUND: In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested. METHODS: The presence of any segmental chromosomal alteration (chromosome 1p deletion, 11q deletion and/ or chromosome 17q gain) defined a segmental genomic profile. Only tumours with a confirmed unaltered status for all three chromosome arms were considered as having no segmental chromosomal alterations. RESULTS: Among the 8800 patients in the INRG database, a genomic type could be attributed for 505 patients without MNA: 397 cases had a segmental genomic type, whereas 108 cases had an absence of any segmental alteration. A segmental genomic type was more frequent in patients > 18 months and in stage 4 disease (P
- Published
- 2012
3. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: Results from the randomized multicenter HIT-SIOP PNET 4 trial
- Author
-
Lannering, B. (Birgitta), Rutkowski, P. (Piotr), Doz, F.F. (François), Pizer, B. (Barry), Gustafsson, G. (Göran), Navajas, A. (Aurora), Massimino, M. (Maura), Reddingius, R.E. (Roel), Benesch, M. (Martin), Carrie, C. (Christian), R. Taylor (Roger), Gandola, L. (Lorenza), Bjor̈k-Eriksson, T. (Thomas), Giralt, S., Oldenburger, F. (Foppe), Pietsch, T. (Torsten), Figarella-Branger, D. (Dominique), Robson, K. (Kathryn), Forni, G. (Gianluca), Clifford, S.C. (Steven), Warmuth-Metz, M. (Monica), Von Hoff, D.D. (Daniel), Faldum, A. (Andreas), Mosseri, V. (Véronique), Kortmann, B., Lannering, B. (Birgitta), Rutkowski, P. (Piotr), Doz, F.F. (François), Pizer, B. (Barry), Gustafsson, G. (Göran), Navajas, A. (Aurora), Massimino, M. (Maura), Reddingius, R.E. (Roel), Benesch, M. (Martin), Carrie, C. (Christian), R. Taylor (Roger), Gandola, L. (Lorenza), Bjor̈k-Eriksson, T. (Thomas), Giralt, S., Oldenburger, F. (Foppe), Pietsch, T. (Torsten), Figarella-Branger, D. (Dominique), Robson, K. (Kathryn), Forni, G. (Gianluca), Clifford, S.C. (Steven), Warmuth-Metz, M. (Monica), Von Hoff, D.D. (Daniel), Faldum, A. (Andreas), Mosseri, V. (Véronique), and Kortmann, B.
- Abstract
Purpose: To compare event-free survival (EFS), overall survival (OS), pattern of relapse, and hearing loss in children with standard-risk medulloblastoma treated by postoperative hyperfractionated or conventionally fractionated radiotherapy followed by maintenance chemotherapy. Patients and Methods: In all, 340 children age 4 to 21 years from 122 European centers were postoperatively staged and randomly assigned to treatment with hyperfractionated radiotherapy (HFRT) or standard (conventional) fractionated radiotherapy (STRT) followed by a common chemotherapy regimen consisting of eight cycles of cisplatin, lomustine, and vincristine. Results: After a median follow-up of 4.8 years (range, 0.1 to 8.3 years), survival rates were not significantly different between the two treatment arms: 5-year EFS was 77% ± 4% in the STRT group and 78% ± 4% in the HFRT group; corresponding 5-year OS was 87% ± 3% and 85% ± 3%, respectively. A postoperative residual tumor of more than 1.5 cm2 was the strongest negative prognostic factor. EFS of children with all reference assessments and no large residual tumor was 82% ± 2% at 5 years. Patients with a delay of more than 7 weeks to the start of RT had a worse prognosis. Severe hearing loss was not significantly different for the two treatment arms at follow-up. Conclusion: In this large randomized European study, which enrolled patients with standard-risk medulloblastoma from more than 100 centers, excellent survival rates were achieved in patients without a large postoperative residual tumor and without RT treatment delays. EFS and OS for HFRT was not superior to STRT, which therefore remains standard of care in this disease.
- Published
- 2012
- Full Text
- View/download PDF
4. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
- Author
-
Schleiermacher, G., Mosseri, V., London, W. B., Maris, J. M., Brodeur, G. M., Attiyeh, E., Haber, M., Khan, J., Nakagawara, A., Speleman, F., Noguera, R., Tonini, G. P., Fischer, M., Ambros, I., Monclair, T., Matthay, K. K., Ambros, P., Cohn, S. L., Pearson, A. D. J., Schleiermacher, G., Mosseri, V., London, W. B., Maris, J. M., Brodeur, G. M., Attiyeh, E., Haber, M., Khan, J., Nakagawara, A., Speleman, F., Noguera, R., Tonini, G. P., Fischer, M., Ambros, I., Monclair, T., Matthay, K. K., Ambros, P., Cohn, S. L., and Pearson, A. D. J.
- Abstract
BACKGROUND: In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested. METHODS: The presence of any segmental chromosomal alteration (chromosome 1p deletion, 11q deletion and/ or chromosome 17q gain) defined a segmental genomic profile. Only tumours with a confirmed unaltered status for all three chromosome arms were considered as having no segmental chromosomal alterations. RESULTS: Among the 8800 patients in the INRG database, a genomic type could be attributed for 505 patients without MNA: 397 cases had a segmental genomic type, whereas 108 cases had an absence of any segmental alteration. A segmental genomic type was more frequent in patients > 18 months and in stage 4 disease (P < 0.0001). In univariate analysis, 11q deletion, 17q gain and a segmental genomic type were associated with a poorer event-free survival (EFS) (P < 0.0001, P = 0.0002 and P < 0.0001, respectively). In multivariate analysis modelling EFS, the parameters age, stage and a segmental genomic type were retained in the model, whereas the individual genetic markers were not (P < 0.0001 and RR = 2.56; P = 0.0002 and RR = 1.8; P = 0.01 and RR = 1.7, respectively). CONCLUSION: A segmental genomic profile, rather than the single genetic markers, adds prognostic information to the clinical markers age and stage in neuroblastoma patients without MNA, underlining the importance of pangenomic studies. British Journal of Cancer (2012) 107, 1418-1422. doi:10.1038/bjc.2012.375 www.bjcancer.com Published online 13 September 2012 (c) 2012 Cancer Research UK
- Published
- 2012
5. Segmental chromosomal alterations have prognostic impact in neuroblastoma: A report from the INRG project
- Author
-
Matthay, Katherine, Matthay, Katherine, Schleiermacher, G, Mosseri, V, London, WB, Maris, JM, Brodeur, GM, Attiyeh, E, Haber, M, Khan, J, Nakagawara, A, Speleman, F, Matthay, Katherine, Matthay, Katherine, Schleiermacher, G, Mosseri, V, London, WB, Maris, JM, Brodeur, GM, Attiyeh, E, Haber, M, Khan, J, Nakagawara, A, and Speleman, F
- Abstract
Background: In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested. Methods: The presence of any segmental chromosomal alteration (chromosome
- Published
- 2012
6. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
- Author
-
Schleiermacher, G., Mosseri, V., London, W. B., Maris, J. M., Brodeur, G. M., Attiyeh, E., Haber, M., Khan, J., Nakagawara, A., Speleman, F., Noguera, R., Tonini, G. P., Fischer, M., Ambros, I., Monclair, T., Matthay, K. K., Ambros, P., Cohn, S. L., Pearson, A. D. J., Schleiermacher, G., Mosseri, V., London, W. B., Maris, J. M., Brodeur, G. M., Attiyeh, E., Haber, M., Khan, J., Nakagawara, A., Speleman, F., Noguera, R., Tonini, G. P., Fischer, M., Ambros, I., Monclair, T., Matthay, K. K., Ambros, P., Cohn, S. L., and Pearson, A. D. J.
- Abstract
BACKGROUND: In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested. METHODS: The presence of any segmental chromosomal alteration (chromosome 1p deletion, 11q deletion and/ or chromosome 17q gain) defined a segmental genomic profile. Only tumours with a confirmed unaltered status for all three chromosome arms were considered as having no segmental chromosomal alterations. RESULTS: Among the 8800 patients in the INRG database, a genomic type could be attributed for 505 patients without MNA: 397 cases had a segmental genomic type, whereas 108 cases had an absence of any segmental alteration. A segmental genomic type was more frequent in patients > 18 months and in stage 4 disease (P < 0.0001). In univariate analysis, 11q deletion, 17q gain and a segmental genomic type were associated with a poorer event-free survival (EFS) (P < 0.0001, P = 0.0002 and P < 0.0001, respectively). In multivariate analysis modelling EFS, the parameters age, stage and a segmental genomic type were retained in the model, whereas the individual genetic markers were not (P < 0.0001 and RR = 2.56; P = 0.0002 and RR = 1.8; P = 0.01 and RR = 1.7, respectively). CONCLUSION: A segmental genomic profile, rather than the single genetic markers, adds prognostic information to the clinical markers age and stage in neuroblastoma patients without MNA, underlining the importance of pangenomic studies. British Journal of Cancer (2012) 107, 1418-1422. doi:10.1038/bjc.2012.375 www.bjcancer.com Published online 13 September 2012 (c) 2012 Cancer Research UK
- Published
- 2012
7. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).
- Author
-
UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Schleiermacher, G, Michon, J, Ribeiro, A, Pierron, G, Mosseri, V, Rubie, H, Munzer, C, Bénard, J, Auger, N, Combaret, V, Janoueix-Lerosey, I, Pearson, A, Tweddle, D A, Bown, N, Gerrard, M, Wheeler, K, Noguera, R, Villamon, E, Cañete, A, Castel, V, Marques, B, de Lacerda, A, Tonini, G P, Mazzocco, K, Defferrari, R, de Bernardi, B, di Cataldo, A, van Roy, N, Brichard, Bénédicte, Ladenstein, R, Ambros, I, Ambros, P, Beiske, K, Delattre, O, Couturier, J, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Schleiermacher, G, Michon, J, Ribeiro, A, Pierron, G, Mosseri, V, Rubie, H, Munzer, C, Bénard, J, Auger, N, Combaret, V, Janoueix-Lerosey, I, Pearson, A, Tweddle, D A, Bown, N, Gerrard, M, Wheeler, K, Noguera, R, Villamon, E, Cañete, A, Castel, V, Marques, B, de Lacerda, A, Tonini, G P, Mazzocco, K, Defferrari, R, de Bernardi, B, di Cataldo, A, van Roy, N, Brichard, Bénédicte, Ladenstein, R, Ambros, I, Ambros, P, Beiske, K, Delattre, O, and Couturier, J
- Abstract
In infants with stage 4s MYCN-non-amplified NB, a SCA genomic profile identifies patients who will require upfront treatment even in the absence of other clinical indication for therapy, whereas in infants with localised unresectable NB, a genomic profile characterised by the absence of SCA identifies patients in whom treatment reduction might be possible. These findings will be implemented in a future international trial.
- Published
- 2011
8. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study.
- Author
-
Verlooy, J, Mosseri, V, Bracard, S, Tubiana, A Lellouch, Kalifa, C, Pichon, F, Frappaz, D, Chastagner, P, Pagnier, A, Bertozzi, A-I, Gentet, J C, Sariban, Eric, Rialland, X, Edan, C, Bours, D, Zerah, M, Le Gales, C, Alapetite, C, Doz, F, Verlooy, J, Mosseri, V, Bracard, S, Tubiana, A Lellouch, Kalifa, C, Pichon, F, Frappaz, D, Chastagner, P, Pagnier, A, Bertozzi, A-I, Gentet, J C, Sariban, Eric, Rialland, X, Edan, C, Bours, D, Zerah, M, Le Gales, C, Alapetite, C, and Doz, F
- Abstract
AIM: Improvement of EFS of children older than 3 years with high risk medulloblastoma. METHODS: Between 1993 and 1999, 115 patients (3-18 years, mean 8 years) with high risk medulloblastoma were included. After surgery treatment consisted of chemotherapy ('8in1' and etoposide/carboplatin) before and after craniospinal radiotherapy. RESULTS: Patients were staged using Chang-criteria (PF residue only, M1 and M2/M3) by local investigator as well as by central review panel (82.4% concordance). Chemotherapy was well tolerated without major delays in radiotherapy. With a mean follow up of 81 months (9-119), 5-year EFS was 49.8% and OS 60.1%. In detail according to subgroups EFS was 68.8% for PF residue only, 58.8% for M1 disease and 43.1% for M2/M3. CONCLUSION: M1 patients are legitimate high risk patients. Survival rates are still very low for high risk medulloblastoma patients and future trials should therefore focus on more intensive (chemotherapy/radiotherapy) treatment., Journal Article, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2006
9. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study.
- Author
-
Verlooy, J, Mosseri, V, Bracard, S, Tubiana, A Lellouch, Kalifa, C, Pichon, F, Frappaz, D, Chastagner, P, Pagnier, A, Bertozzi, A-I, Gentet, J C, Sariban, Eric, Rialland, X, Edan, C, Bours, D, Zerah, M, Le Gales, C, Alapetite, C, Doz, F, Verlooy, J, Mosseri, V, Bracard, S, Tubiana, A Lellouch, Kalifa, C, Pichon, F, Frappaz, D, Chastagner, P, Pagnier, A, Bertozzi, A-I, Gentet, J C, Sariban, Eric, Rialland, X, Edan, C, Bours, D, Zerah, M, Le Gales, C, Alapetite, C, and Doz, F
- Abstract
AIM: Improvement of EFS of children older than 3 years with high risk medulloblastoma. METHODS: Between 1993 and 1999, 115 patients (3-18 years, mean 8 years) with high risk medulloblastoma were included. After surgery treatment consisted of chemotherapy ('8in1' and etoposide/carboplatin) before and after craniospinal radiotherapy. RESULTS: Patients were staged using Chang-criteria (PF residue only, M1 and M2/M3) by local investigator as well as by central review panel (82.4% concordance). Chemotherapy was well tolerated without major delays in radiotherapy. With a mean follow up of 81 months (9-119), 5-year EFS was 49.8% and OS 60.1%. In detail according to subgroups EFS was 68.8% for PF residue only, 58.8% for M1 disease and 43.1% for M2/M3. CONCLUSION: M1 patients are legitimate high risk patients. Survival rates are still very low for high risk medulloblastoma patients and future trials should therefore focus on more intensive (chemotherapy/radiotherapy) treatment., Journal Article, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2006
10. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study.
- Author
-
Oyharcabal-Bourden, V, Kalifa, C, Gentet, J C, Frappaz, D, Edan, C, Chastagner, P, Sariban, Eric, Pagnier, A, Babin, A, Pichon, F, Neuenschwander, S, Vinchon, Mathieu, Bours, D, Mosseri, V, Le Gales, C, Ruchoux, Marie-Magdeleine, Carrie, C., Doz, F, Oyharcabal-Bourden, V, Kalifa, C, Gentet, J C, Frappaz, D, Edan, C, Chastagner, P, Sariban, Eric, Pagnier, A, Babin, A, Pichon, F, Neuenschwander, S, Vinchon, Mathieu, Bours, D, Mosseri, V, Le Gales, C, Ruchoux, Marie-Magdeleine, Carrie, C., and Doz, F
- Abstract
OBJECTIVE: The primary objective of this study was to decrease the late effects of prophylactic radiation without reducing survival in standard-risk childhood medulloblastoma. PATIENTS AND METHODS: Inclusion criteria were as follows: children between the ages of 3 and 18 years with total or subtotal tumor resection, no metastasis, and negative postoperative lumbar puncture CSF cytology. Two courses of eight drugs in 1 day followed by two courses of etoposide plus carboplatin (500 and 800 mg/m(2) per course, respectively) were administered after surgery. Radiation therapy had to begin 90 days after surgery. Delivered doses were 55 Gy to the posterior fossa and 25 Gy to the brain and spinal canal. RESULTS: Between November 1991 and June 1998, 136 patients (median age, 8 years; median follow-up, 6.5 years) were included. The overall survival rate and 5-year recurrence-free survival rate were 73.8% +/- 7.6% and 64.8% +/- 8.1%, respectively. Radiologic review showed that 4% of patients were wrongly included. Review of radiotherapy technical files demonstrated a correlation between the presence of a major protocol deviation and treatment failure. The 5-year recurrence-free survival rate of patients included in this study with all optimal quality controls of histology, radiology, and radiotherapy was 71.8% +/- 10.5%. In terms of sequelae, 31% of patients required growth hormone replacement therapy and 25% required special schooling. CONCLUSION: Reduced-dose craniospinal radiation therapy can be proposed in standard-risk medulloblastoma provided staging and radiation therapy are performed under optimal conditions., Journal Article, Research Support, Non-U.S. Gov't, info:eu-repo/semantics/published
- Published
- 2005
11. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study.
- Author
-
Oyharcabal-Bourden, V, Kalifa, C, Gentet, J C, Frappaz, D, Edan, C, Chastagner, P, Sariban, Eric, Pagnier, A, Babin, A, Pichon, F, Neuenschwander, S, Vinchon, Mathieu, Bours, D, Mosseri, V, Le Gales, C, Ruchoux, Marie-Magdeleine, Carrie, C., Doz, F, Oyharcabal-Bourden, V, Kalifa, C, Gentet, J C, Frappaz, D, Edan, C, Chastagner, P, Sariban, Eric, Pagnier, A, Babin, A, Pichon, F, Neuenschwander, S, Vinchon, Mathieu, Bours, D, Mosseri, V, Le Gales, C, Ruchoux, Marie-Magdeleine, Carrie, C., and Doz, F
- Abstract
OBJECTIVE: The primary objective of this study was to decrease the late effects of prophylactic radiation without reducing survival in standard-risk childhood medulloblastoma. PATIENTS AND METHODS: Inclusion criteria were as follows: children between the ages of 3 and 18 years with total or subtotal tumor resection, no metastasis, and negative postoperative lumbar puncture CSF cytology. Two courses of eight drugs in 1 day followed by two courses of etoposide plus carboplatin (500 and 800 mg/m(2) per course, respectively) were administered after surgery. Radiation therapy had to begin 90 days after surgery. Delivered doses were 55 Gy to the posterior fossa and 25 Gy to the brain and spinal canal. RESULTS: Between November 1991 and June 1998, 136 patients (median age, 8 years; median follow-up, 6.5 years) were included. The overall survival rate and 5-year recurrence-free survival rate were 73.8% +/- 7.6% and 64.8% +/- 8.1%, respectively. Radiologic review showed that 4% of patients were wrongly included. Review of radiotherapy technical files demonstrated a correlation between the presence of a major protocol deviation and treatment failure. The 5-year recurrence-free survival rate of patients included in this study with all optimal quality controls of histology, radiology, and radiotherapy was 71.8% +/- 10.5%. In terms of sequelae, 31% of patients required growth hormone replacement therapy and 25% required special schooling. CONCLUSION: Reduced-dose craniospinal radiation therapy can be proposed in standard-risk medulloblastoma provided staging and radiation therapy are performed under optimal conditions., Journal Article, Research Support, Non-U.S. Gov't, info:eu-repo/semantics/published
- Published
- 2005
12. Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Société Française d'Oncologie Pédiatrique.
- Author
-
Doz, F, Neuenschwander, S, Bouffet, E, Gentet, J C, Schneider, P, Kalifa, C, Mechinaud, F, Chastagner, P, De Lumley, L, Sariban, Eric, Plantaz, D, Mosseri, V, Bours, D, Alapetite, C, Zucker, J M, Doz, F, Neuenschwander, S, Bouffet, E, Gentet, J C, Schneider, P, Kalifa, C, Mechinaud, F, Chastagner, P, De Lumley, L, Sariban, Eric, Plantaz, D, Mosseri, V, Bours, D, Alapetite, C, and Zucker, J M
- Abstract
Childhood malignant brain stem tumours have a very poor prognosis with a median survival of 9 months despite radiotherapy. No chemotherapy has improved survival. However, carboplatin has been reported to have activity in glial tumours as well as antitumour synergy with radiation. Our aims were to test the response rate of these tumours to carboplatin alone and to evaluate the efficacy on survival of carboplatin alone followed by concurrent carboplatin and radiotherapy. Patients younger than 16 years with typical clinical and radiological presentation of infiltrating brain stem tumour, as well as histologically-documented cases in the atypical forms, were eligible. Two courses of carboplatin (1050 mg/m2 over 3 days) were administered initially. This treatment was followed by a chemoradiotherapy phase including five weekly carboplatin courses (200 mg/m2) and conventional radiotherapy. 38 eligible patients were included. No tumour response was observed after the initial phase. This schedule of first-line carboplatin followed by concurrent carboplatin and radiotherapy did not improve survival., Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2002
13. Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Société Française d'Oncologie Pédiatrique.
- Author
-
Doz, F, Neuenschwander, S, Bouffet, E, Gentet, J C, Schneider, P, Kalifa, C, Mechinaud, F, Chastagner, P, De Lumley, L, Sariban, Eric, Plantaz, D, Mosseri, V, Bours, D, Alapetite, C, Zucker, J M, Doz, F, Neuenschwander, S, Bouffet, E, Gentet, J C, Schneider, P, Kalifa, C, Mechinaud, F, Chastagner, P, De Lumley, L, Sariban, Eric, Plantaz, D, Mosseri, V, Bours, D, Alapetite, C, and Zucker, J M
- Abstract
Childhood malignant brain stem tumours have a very poor prognosis with a median survival of 9 months despite radiotherapy. No chemotherapy has improved survival. However, carboplatin has been reported to have activity in glial tumours as well as antitumour synergy with radiation. Our aims were to test the response rate of these tumours to carboplatin alone and to evaluate the efficacy on survival of carboplatin alone followed by concurrent carboplatin and radiotherapy. Patients younger than 16 years with typical clinical and radiological presentation of infiltrating brain stem tumour, as well as histologically-documented cases in the atypical forms, were eligible. Two courses of carboplatin (1050 mg/m2 over 3 days) were administered initially. This treatment was followed by a chemoradiotherapy phase including five weekly carboplatin courses (200 mg/m2) and conventional radiotherapy. 38 eligible patients were included. No tumour response was observed after the initial phase. This schedule of first-line carboplatin followed by concurrent carboplatin and radiotherapy did not improve survival., Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.